Ryvu Therapeutics S.A. (WSE:RVU)
Poland · Delayed Price · Currency is PLN 23.55
+0.15 (0.64%)
Apr 8, 2026, 5:00 PM CET
Ryvu Therapeutics Revenue
In the year 2025, Ryvu Therapeutics had annual revenue of 87.70M PLN, down -13.98%. Ryvu Therapeutics had revenue of 25.78M in the quarter ending December 31, 2025, a decrease of -9.50%.
Revenue
87.70M
Revenue Growth
-13.98%
P/S Ratio
6.17
Revenue / Employee
384.66K
Employees
228
Market Cap
541.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 87.70M | -14.26M | -13.98% |
| Dec 31, 2024 | 101.96M | 34.67M | 51.51% |
| Dec 31, 2023 | 67.30M | -1.14M | -1.67% |
| Dec 31, 2022 | 68.44M | 33.02M | 93.25% |
| Dec 31, 2021 | 35.41M | -1.54M | -4.16% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BIOTON | 282.52M |
| Synthaverse | 71.76M |
| Mabion | 14.81M |
| Captor Therapeutics Spolka Akcyjna | 7.57M |
| Molecure | 5.86M |
| Urteste | 1.80M |
| Pharmena | 1.58M |
| Poltreg | 250.00K |